CEO Change Disclosure
-
CEO changed from Kim Seong-jin to Woo Jeong-won (effective 2026-05-15)
-
Reason: Enhance management expertise and efficiency
-
New CEO Woo Jeong-won (born 1960, 0.09% stake)
-
Previously CEO of Genexine (KOSDAQ listed) from 2013 to 2023
-
Board resolution date: 2026-05-15, 2 outside directors attended, auditor attended
KOSDAQ Filing Information
-
Filing: Change In Representative Director
-
Company: MedPacto (235980)
-
Submission: MedPacto, Inc.
-
Receipt: 05-15-2026
-
Under KRX KOSDAQ Market Division